You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Details for Patent: 8,241,664


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,241,664 protect, and when does it expire?

Patent 8,241,664 protects JATENZO and is included in one NDA.

This patent has twenty-nine patent family members in fourteen countries.

Summary for Patent: 8,241,664
Title:Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
Abstract: A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.
Inventor(s): Dudley; Robert E. (Rosemary Beach, IL), Constantinides; Panayiotis P. (Gurnee, IL)
Assignee: Clarus Therapeutics, Inc (Northbrook, IL)
Application Number:11/911,446
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,241,664
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 8,241,664

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Tolmar JATENZO testosterone undecanoate CAPSULE;ORAL 206089-001 Mar 27, 2019 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y METHOD OF TREATING TESTOSTERONE DEFICIENCY ⤷  Try a Trial
Tolmar JATENZO testosterone undecanoate CAPSULE;ORAL 206089-002 Mar 27, 2019 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y METHOD OF TREATING TESTOSTERONE DEFICIENCY ⤷  Try a Trial
Tolmar JATENZO testosterone undecanoate CAPSULE;ORAL 206089-003 Mar 27, 2019 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y METHOD OF TREATING TESTOSTERONE DEFICIENCY ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,241,664

PCT Information
PCT FiledApril 14, 2006PCT Application Number:PCT/US2006/014207
PCT Publication Date:October 26, 2006PCT Publication Number: WO2006/113505

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.